Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row

After Brookline Capital Markets and Truist Financial gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received another Buy, this time from JMP Securities. Analyst Silvan Tuerkcan maintained a Buy rating on Crispr Therapeutics AG today and set a price target of $150.00. The company’s shares closed last Monday at $61.37, close to its 52-week low of $50.54.

According to, Tuerkcan is a 3-star analyst with an average return of 6.4% and a 36.0% success rate. Tuerkcan covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Logicbio Therapeutics, and Intellia Therapeutics.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $116.83, which is a 96.1% upside from current levels. In a report issued on February 14, Brookline Capital Markets also initiated coverage with a Buy rating on the stock with a $143.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $169.76 and a one-year low of $50.54. Currently, Crispr Therapeutics AG has an average volume of 1.63M.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read More on CRSP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More